The tracer demonstrated high and reliable uptake rates in primary cancers, binding to human FAP at sub‐nanomolar concentrations; due to its low molecular weight, the tracer accumulated rapidly and displayed low immunogenicity [286]. This evidence concerns the gene FAP and cancer.